ANTIMALARIAL EFFICACY STUDIES

Since 1998, the MU-UCSF Research Collaboration has conducted a large number of observational and efficacy trials of antimalarial treatments in cohorts located in Kampala or Tororo, Uganda. These trials included the study of:

• Chloroquine (CQ), August 1998 to March 1999

• CQ vs. sulfadoxine-pyrimethamine (SP), March 1999 to August 1999

• SP vs. amodiaquine (AQ) v. SP plus AQ (SP + AQ), September 1999 to July 2000

• SP vs. SP + AQ vs. SP plus artesunate (SP + AS), July 2000 to August 2001

• SP vs. SP + AQ vs. SP plus CQ (SP + CQ), March 2001 to January 2002

• SP + CQ vs. SP + AQ vs. AQ plus AS (AQ + AS), October 2002 to June 2003

• AQ + AS vs. AQ + AS vs. artemether-lumefantrine (AL), November 2004 to December 2008 [See Mulago III Cohort study] ]

• AQ + AS in HIV+ children, Oct 2005 to May 2009[See CHAMP study]

• AL vs. dihydroartemisinin-piperaquine (DP) in HIV+ or exposed children withTMP/SMX prophylaxis, August 2007 - ongoing [See TCC study]  

Results of antimalarial drug efficacy trials


Treatment*

Number of studies

Total number enrolled

Risk of recurrent malaria
median (range)**

Risk of recrudescence
median (range)†

CQ
SP
AQ
CQ+SP
AQ+SP
AS+SP
AS+AQ
AL
DP

2
4
1
9
12
1
7
4
2

352
604
147
1534
2133
198
1301
815
426

80% (80-89%)
46% (30-60%)
32%
69% (17-88%)
32% (1-55%)
29%
43% (17-75%)
36% (7-53%)
28% (12-43%)

Not available
29%
Not available
41% (25-64%)
14% (1-32%)
19%
7% (3-13%)
8% (1-16%)
5% (2-7%)

* CQ=chloroquine; SP=sulfadoxine-pyrimethamine; AQ=amodiaquine; AS=artesunate; AL=artemether-lumefantrine; DP=dihydroartemisinin-piperaquine**All episodes of malaria occurring within 28 days after therapy †Recrudescence of initial infections within 28 days after therapy, distinguished from new infections by molecular genotyping